Concepedia

Author

Azadeh Nasrazadani

University of PittsburghORCID

Also Known As

A Nasrazadani, A. Nasrazadani, AZADEH NASRAZADANI, Azadeh Nasrazadani, Bora Lim

81

Publications

729

Citations

15

H-Index

14

Concepts

All Affiliations

University of PittsburghDana-Farber Cancer InstituteMagee-Womens Research InstituteThe University of Texas MD Anderson Cancer CenterUniversity of Pittsburgh Medical Center
AN

About

Azadeh Nasrazadani is an author at University of Pittsburgh specializing in medicine, tumor biology, and tumor microenvironment.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

2

2

44

2

Cell Biology

2

2

44

3

Pharmacology

1

1

19

4

Cancer Therapeutics

1

1

19

5

Cell Signaling

1

1

25

Azadeh Nasrazadani

×

10

Publications

366

Citations

10

H-Index

YearCitations

Clinical Outcomes With Abemaciclib After Prior CDK4/6 Inhibitor Progression in Breast Cancer: A Multicenter Experience

Seth A. Wander, Hyo S. Han, Mark L. Zangardi,

Journal of the National Comprehensive Cancer Network

2021

82

Hotspot <i>ESR1</i> Mutations Are Multimodal and Contextual Modulators of Breast Cancer Metastasis

Zheqi Li, Yang Wu, Megan E. Yates,

Cancer Research

2022

78

Clinicopathological Features and Outcomes Comparing Patients With Invasive Ductal and Lobular Breast Cancer

Steffi Oesterreich, Azadeh Nasrazadani, Jian Zou,

JNCI Journal of the National Cancer Institute

2022

64

Jnk2 Effects on Tumor Development, Genetic Instability and Replicative Stress in an Oncogene-Driven Mouse Mammary Tumor Model

Peila Chen, Jamye F. O’Neal, Nancy D. Ebelt,

PLoS ONE

2010

47

c-Jun N-terminal Kinase 2 Regulates Multiple Receptor Tyrosine Kinase Pathways in Mouse Mammary Tumor Growth and Metastasis

Azadeh Nasrazadani, Carla L. Van Den Berg

Genes & Cancer

2011

25

Triple-Negative Breast Cancer and Emerging Therapeutic Strategies: ATR and CHK1/2 as Promising Targets

Amalia A. Sofianidi, Ecaterina E. Dumbrava, Konstantinos N. Syrigos,

Cancers

2024

19

A Gene Panel Associated With Abemaciclib Utility in <i>ESR1</i>-Mutated Breast Cancer After Prior Cyclin-Dependent Kinase 4/6-Inhibitor Progression

Jamie O. Brett, Taronish D. Dubash, Gabriela N. Johnson,

JCO Precision Oncology

2023

15

Spatial molecular profiling of mixed invasive ductal and lobular breast cancers reveals heterogeneity in intrinsic molecular subtypes, oncogenic signatures, and mutations

Osama Shiraz Shah, Azadeh Nasrazadani, Julia Foldi,

Proceedings of the National Academy of Sciences

2024

15

Breast cancer mortality as a function of age

Azadeh Nasrazadani, Juan Luis Gomez Marti, Kevin E. Kip,

Aging

2022

11

Solid tumour-induced systemic immunosuppression involves dichotomous myeloid–B cell interactions

Xiaoxin Hao, Yichao Shen, Jun Liu,

Nature Cell Biology

2024

10

Page 1